Aspireo Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly

The study was designed to investigate the safety, tolerability and efficacy of single ascending doses of Somatoprim (DG3173) in up to 20 treatment-naïve acromegaly patients.

Analysis of the results shows that Somatoprim demonstrated a dose-dependent effect on lowering excess growth hormone (hGH) on treatment-naïve patients suffering from acromegaly. No serious adverse events were reported and the reported adverse events were mild to moderate and of transient nature.

Carsten Dehning, CEO of Aspireo said: “The result of this clinical study provides proof-of-concept that Somatoprim has the potential to be a safe and effective treatment for acromegaly. An analysis of the pharmacodynamic and pharmacokinetic relationship gives us further valuable insight into the dose dependent effectiveness of Somatoprim in reducing growth hormone secretion.”